SCHEMBL25519699

SCHEMBL25519699

Cc1ccc(N)c(S(=O)(=O)C2CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 2/20 0.42
CYP3A4 P08684 2/20 0.42
ALOX15 P16050 2/20 0.42
THRB P10828 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 2/20 0.37
TSHR P16473 3/20 0.37
FEN1 P39748 2/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341155 0.93 SMN1; SMN2 (0.41) SMN1; SMN2TDP1TP53CYP3A4ALOX15
SCHEMBL25519675 0.81 ALDH1A1 (0.46) SMN1; SMN2TDP1L3MBTL1ALDH1A1KDM4E
SCHEMBL25519678 0.79 L3MBTL1 (0.39) SMN1; SMN2TP53L3MBTL1ALDH1A1TSHR
SCHEMBL20150187 0.75 CYP3A4 (0.50) SMN1; SMN2TDP1TP53CYP3A4ALOX15
SCHEMBL30908409 0.75 CYP3A4 (0.50) SMN1; SMN2TDP1TP53CYP3A4ALOX15
SCHEMBL1522533 0.75 ALDH1A1 (0.59) SMN1; SMN2TDP1TP53CYP3A4ALOX15
SCHEMBL31251140 0.73 GAA (0.56) SMN1; SMN2CYP3A4ALOX15FEN1CASP1
SCHEMBL8776028 0.73 CYP3A4 (0.48) SMN1; SMN2TDP1TP53CYP3A4ALOX15
SCHEMBL13380519 0.73 GAA (0.56) SMN1; SMN2CYP3A4ALOX15FEN1CASP1
SCHEMBL13379613 0.73 CYP3A4 (0.48) SMN1; SMN2TDP1TP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM SMN1; SMN2 420/4885TDP1 94/4885TP53 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.